Thank you, Minister.
I would like to emphasize that the work that has been done at the laboratory over the past 16 months has been born out of a long-standing history of responding to important events, be it domestically or internationally, through the outbreak support we have gotten. The research we have done has advanced our knowledge and our ability to respond to these diseases. It's the day-to-day toil of our staff that makes the work possible, through collaboration.
Through that collaboration, there are a number of achievements I want to read into the record, including the development of a Sudan vaccine candidate, which is a subtype of Ebola. There has been the identification of losmapimod, which is able to block Lassa virus entry. There has been the characterization of Tangeretin, which is a novel blocker of cellular entry for viral hemorrhagic fevers. There has been the development of treatment for potential Rift Valley fever, and novel treatments against Ebola and other high-consequence pathogens.
All of that work is something we are very proud of, and it is born out of the work of our staff, who collaborate to advance the health, safety and security of Canadians and the rest of the globe.